Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00645840

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes

An Exploratory, Open Label Study of Anti-inflammatory Therapy With Anakinra in Children With Newly Diagnosed Type 1 Diabetes Mellitus

Sponsor: Children's Medical Center Dallas

Conditions Type 1 Diabetes Mellitus

Interventions Anakinra

Updated 8 times since 2017 Last updated: Oct 24, 2019 Started: Mar 31, 2008 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Type 1 Diabetes Mellitus and is currently completed. Children's Medical Center Dallas leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1_PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2019 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Medical Center Dallas
University of Texas Southwestern Medical Center

Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States